Market Data graphic

Life Sciences

You are here

The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.

Life sciences companies listed on CSE

1CM Inc. is a retailer of vice consumer staples in Canada including Cannabis, Alcohol, Tobacco, Nicotine Vape, and CPG (Consumer Packaged Goods). Our vision is to be Canada's leading vice consumer staples retailer and wholesaler. The Company is focused on expanding its current operations through organic growth and by way of merger and acquisition transactions.

4Front Ventures Corp. is a vertically-integrated cannabis company with cultivation, production and retail facilities spread across several states in the US.

Share Classes

4Front has two classes of shares: subordinate voting shares (“SVS”) and multiple voting shares (“MVS”). SVS are publicly traded on the CSE and are entitled to one vote.  MVS are not publicly traded, can convert to SVS at a ratio of 1 MVS to 1 SVS, and are entitled to 800 votes per MVS.

There are 668,243,141 SVS outstanding and 1,276,208 MVS convertible to 1,276,208 outstanding for a total outstanding SVS of 659,519,347 on an as-converted basis.

Please see Section 10 - Description of Securities of 4Front's Form 2A Listing Statement for a further description of the SVS and MVS.

Headquartered in New York City, Acreage is a vertically integrated, multi-state operator of cannabis ‎licenses and assets in the U.S. Acreage is dedicated to building and scaling operations to create a ‎seamless, consumer-focused branded cannabis experience. Acreage debuted its national retail store ‎brand, The Botanist in 2018 and its award-winning consumer brands, The Botanist and Live Resin Project ‎in 2019.‎

Class E subordinate voting share (each, a “Fixed Share”) of the Company was created pursuant to the Amended Plan of Arrangement.  Each Fixed Share entitles the holder to one vote per share at shareholder meetings of the Company. Each Fixed Share is subject to an option (the “Canopy Option”) in favour of Canopy Growth Corporation (“Canopy Growth”) pursuant to which Canopy Growth may, upon satisfaction or waiver of the conditions set out in the Amended Arrangement Agreement, acquire the Fixed Shares (the “Acquisition”).  The  Canopy Option is required to be exercised upon the occurrence of changes in U.S. federal law to permit the general cultivation, distribution, and possession of marijuana and subject to the satisfaction or waiver of certain conditions to closing as set out in the Amended Arrangement Agreement, the Acquisition will be completed.

Investor Note: In addition to the 71,343,094 Fixed Shares and 30,626,805 Floating Shares that are listed and trading, there are 17,017,664 Fixed Shares and 7,242,885 Floating Shares, respectively, reserved for issuance pursuant to redemption and conversion rights attached to other share classes of Acreage Holdings, Inc., as well as certain outstanding securities of Acreage Holdings WC, Inc. and High Street Capital Partners, LLC, which are subsidiaries of Acreage Holdings, Inc. The total number of Fixed Shares and Floating Shares, as converted, is 88,360,758 and 37,869,690, respectively, excluding options, warrants, RSUs and convertible debt.

 

Headquartered in New York City, Acreage is a vertically integrated, multi-state operator of cannabis ‎licenses and assets in the U.S. Acreage is dedicated to building and scaling operations to create a ‎seamless, consumer-focused branded cannabis experience.

A Class D subordinate voting share (each, a “Floating Share”) of the Company was created pursuant to the Amended Plan of Arrangement.  Each Floating Share entitles the holder thereof to one vote per share at shareholder meetings of the Company. Each Fixed Share is subject to an option in favor of Canopy Growth (the “Floating Call Option”) to acquire all of the issued and outstanding Floating Shares.  If exercised in accordance with the terms of the Amended Plan of Arrangement, Canopy Growth’s acquisition of the Floating Shares will take place concurrently with, and subject to satisfaction or waiver of the same conditions as, the Acquisition.

Investor Note: In addition to the 71,343,094 Fixed Shares and 30,626,805 Floating Shares that are listed and trading, there are 17,017,664 Fixed Shares and 7,242,885 Floating Shares, respectively, reserved for issuance pursuant to redemption and conversion rights attached to other share classes of Acreage Holdings, Inc., as well as certain outstanding securities of Acreage Holdings WC, Inc. and High Street Capital Partners, LLC, which are subsidiaries of Acreage Holdings, Inc. The total number of Fixed Shares and Floating Shares, as converted, is 88,360,758 and 37,869,690, respectively, excluding options, warrants, RSUs and convertible debt.

Founded in 2014, Adastra Holdings Ltd. through its Health Canada licensed subsidiary, Adastra Labs has built a successful reputation as a leading cannabis processor. Adastra manufactures products for its successful in-house concentrates brands Phyto Extractions and Endgame Extracts and co-manufactures for many Canadian cannabis brands. With products sold at more than 2,000 retailers across the country.

Operating out of its 13,500 sq. ft. Health Canada Licensed Standard Processing and co-located analytical testing lab facility, Adastra produces and distributes cannabis-derived products designed for medical cannabis and forward-looking therapeutic use. 

Adastra received its controlled substances dealer's license in August 2022 with an amendment in February 2023 and is licensed to partner with healthcare professionals and practitioners within the regulated environment to help create efficacious remedies that address the actual needs of patients.

 

 

Affinor is focused on the design, development and commercialization of vertical farming technology for both indoor and outdoor (greenhouse) applications. The team is currently working on demand crops such as romaine lettuce and strawberries by developing processes, methods and models to cultivate true perpetual crops at competitive pricing. It is the mission of Affinor to be the world-wide technology and market leader in creating and commercializing the most economical vertical farming technologies that use the least possible resources (eg. land, water, and energy resources) to produce the highest quality pesticide-free produce year-round, regardless of environmental conditions. Affinor’s patent technology and licensed patent pending technology positions the Company well in the vertical farming industry. It is the only vertically integrated technology that can offer patented inline automated pollination for fruiting crops. Affinor can offer software driven growing solutions automating high quality, scientifically engineered products and process.

The Issuer is a digital health solutions provider utilizing a proprietary combination of digital health monitoring devices, AI based software, and a cloud computing platform which combine to help care givers, patients and healthcare professionals access and utilize relevant health data.

Aion Therapeutic is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.

Albert Labs International Corp. is a research and drug development company addressing mental health care needs. Through a succinct clinical pathway, focusing on Real World Evidence (RWE) Albert Labs look to commercialize its psychedelic-based treatments, and in doing so deliver psychedelic-assisted psychotherapy to patients sooner. Focused on accelerating access and faster approvals, Albert Labs put patients with urgent and unmet needs first as it develops licensed medicines to treat a variety of mental health conditions. Cancer-related distress, an initial focus of Albert Labs development program is thought to affect over 16 million patients worldwide.

Algernon Pharmaceuticals is a drug re-purposing company that investigates safe, already approved drugs for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing.

Contact The Team

How can we help you?

Contact the CSE team to find out more.